Peroxisome proliferator-activated receptor gamma (PPARc) is a master regulator for white adipocyte differentiation and lipid storage. The increased level of hepatic PPARc2 isoform reprograms liver for lipid storage and causes abnormal fat accumulation in certain pathophysiologic conditions. The current study aimed to investigate a role of transcriptional repressor hairy and enhancer of split 6 (HES6) in the regulation of Pparg2 expression and hepatic steatosis induced by diet. Liver-specific overexpression of Hes6 using adenovirus reduced Pparg2 messenger RNA levels by 90% and hepatic triglyceride accumulation by 22% compared to the levels in mice injected with an adenoviral empty vector with Western diet feeding. In sharp contrast, silencing Hes6 gene expression using short hairpin RNA increased hepatic lipid accumulation and Pparg2 messenger RNA levels by 70% and 4-fold, respectively. To locate hepatocyte nuclear factor 4 alpha (HNF4a) binding site(s), through which repressional activity of HES6 is mediated, a 2.5-kb Pparg2 promoter-driven luciferase reporter was constructed for transient transfection assays. Subsequently, chromatin immunoprecipitation and electrophoretic mobility shift assays were performed. An HNF4a binding consensus sequence was identified at 903 base pairs upstream from the transcription start site of Pparg2. Deletion or point mutation of the sequence in a luciferase reporter containing the Pparg2 promoter abolished HNF4a-mediated activation in HeLa cells. Chromatin immunoprecipitation and electrophoretic mobility shift assays further confirmed direct recruitment and binding of HNF4a to the site. Gene expression analysis with liver samples from subjects with nonalcoholic steatohepatitis suggested that the axis of the Hes6-Hnf4a-Pparg2 transcriptional cascade is also responsible for hepatic fat accumulation in humans. Conclusion: HES6 represses Pparg2 gene expression, thereby preventing hepatic lipid accumulation induced by chronic Western diet feeding
Introduction
T he liver is the major organ for synthesizing and delivering triglycerides in the form of very low density lipoprotein (VLDL) to other peripheral tissues, such as muscle and adipocytes, for energy use or storage. (1) Fat accumulation in the liver is considered the initial step before proceeding into nonalcoholic steatohepatitis (NASH). Under certain pathophysiologic conditions, such as insulin resistance or obesity, lipid homeostasis in the liver can be disrupted and hepatic steatosis ensues. A subsequent insult presented by inflammation, oxidative stress, or dietary factors would advance benign steatosis into the next disease stage, which is NASH. (2) Those insults can originate from other peripheral sources, such as macrophages, adipocytes, and intestinal gut bacteria. (3, 4) Unlike the underlying mechanisms of how these second hits strike, pathways involved in hepatic lipid accumulation have been relatively well studied and documented. (5, 6) Abbreviations: Ad, adenovirus; Adnull, adenovirus without an insert; cDNA, complementary DNA; ChIP, chromatic immunoprecipitation; CIDEC, cell death inducing DFFA like effector C; CoA, coenzyme A; CrebH, cyclic-adenosine monophosphate-response-element binding protein H; EMSA, electrophoretic mobility shift assay; Fsp27, fat specific protein 27; Hes6, hairy and enhancer of split 6; Hnf4a, hepatocyte nuclear factor 4 alpha; mRNA, messenger RNA; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; Ppar, peroxisome proliferator activated receptor; RAR, retinoic acid receptor; sh, short hairpin; Shp, small heterodimer partner; TG, triacylglycerol; VLDL, very low density lipoprotein; WD, Western diet.
Circulating fatty acids from white adipose tissues mainly contribute to hepatic fat accumulation rather than fatty acids from de novo synthesis. (2) One of the suggested driving forces for this fat accumulation is induction of the nuclear hormone receptor peroxisome proliferatoractivated receptor gamma (PPARc), especially the PPARc2 (hepatocyte-specific isoform)-associated lipogenic program. (7, 8) In a recent study, Matsusue et al. (9) reported that PPARc directly activates expression of fatspecific protein 27/cell death inducing DFFA like effector C (Fsp27/CIDEC) in the liver, thereby promoting hepatic steatosis. As a lipid droplet binding protein, FSP27 has been reported to protect lipid droplets from enzymatic hydrolysis and maintain triacylglycerol (TG) storage in adipose tissues. (10) (11) (12) This functional property of the protein is a major mechanism underlying hepatic steatosis induced by PPARc. (9) The orphan nuclear hormone receptor small heterodimer partner (Shp, Nr0b2) is involved in bile acid, lipid, and glucose metabolism. Shp -/-mice displayed a protective phenotype against diet-induced obesity and hepatic steatosis. (13, 14) We have shown that the deletion of Shp directly derepresses transcriptional activity of PPARa, thereby inducing the expression of its target genes, especially those involved in fatty acid oxidation, such as carnitine palmitoyltransferase 1 alpha and acyl-coenyzme A (CoA) oxidase 1. (14) The loss of Shp also resulted in lower expressions of Pparg2 and Fsp27 in the liver, which is mediated through a transcriptional cascade, including a novel repressor hairy and enhancer of split 6 (HES6). (15) The mouse Hes6 gene was cloned in an attempt to isolate transcriptional regulators in muscle and neuronal differentiation using degenerate primers targeting basic domain helix-loop-helix transcription factors. (16) Unlike other basic helix-loop-helix proteins, HES6 promotes neuronal differentiation without DNA binding. This may be achieved by inhibition of HES1-mediated transcription, which negatively regulates muscle and neuronal differentiation, through direct protein-protein interaction. (17) (18) (19) The term Hes originated from its structural homology of the Drosophila hairy and enhancer of split proteins. (17) Other than the described muscle and neuronal function, HES6 plays roles in hepatic lipid metabolism. (20) In one of the proposed roles, HES6 interacts with nuclear hormone receptor hepatocyte nuclear factor 4 alpha (HNF4a) to repress the expression of Pparg, which encodes a positive regulator in lipogenic and adipogenic programs. Our recent study revealed that nuclear receptor Shp and retinoic acid receptor (RAR) coordinately regulate Hes6 gene expression. (15) Overexpression or activation of hepatic RAR by adenovirus or all trans retinoic acid treatment increased expression of Hes6 and reduced Pparg2 and Fsp27 gene expression, which inhibits hepatic lipid accumulation.
In the current study, we investigated the effect of HES6 on Pparg2 gene expression and hepatic steatosis in mice through adenovirus-mediated overexpression and silencing and identified a responsive sequence, mediated through HNF4a, on the Pparg2 promoter region by using transient transfection and gel electrophoretic mobility shift assays.
Hes6 in mouse liver, adenovirus containing Hes6 (AdHes6) complementary DNA (cDNA) was injected into 4-month-old mice fed a Western diet (WD) (TD.88137; Envigo, Madison, WI) for 2 months in advance through the tail vein in a dose of 1 3 10 9 plaque-forming units per mouse. To silence Hes6 expression in mouse liver, adenovirus expressing short hairpin RNA (shRNA) targeting the Hes6 gene was delivered into 3-month-old mice fed chow with the same dose. The mice were maintained on a WD for an additional 2 weeks, and their blood and tissues were collected after overnight fasting. All mice were housed in the accredited pathogen-free facility at Northeast Ohio Medical University on a 12-hour light-dark cycle and with free access to diets and water. All animal experiments were based on the protocols reviewed and approved by the Institutional Animal Care and Use Committee of Northeast Ohio Medical University.
CONSTRUCTION OF ADENOVIRUSES
The mouse Hes6 cDNA clone was purchased from Open Biosystems (Dharmacon, Lafayett, CO) and subcloned into a pacAd5 cytomegalovirus shuttle vector to generate AdHes6 based on the protocols provided by the manufacturer (Cell Biolabs Inc., San Diego, CA). In order to design shRNA for mouse Hes6, small interfering RNA Wizard and BLOCK-iT RNAi Designer (InvivoGen) were used. The designed oligonucleotides were synthesized, and annealed double-stranded DNAs were subcloned into a pacAd5 cytomegalovirus shuttle vector to generate four AdshHes6 constructs. After testing the efficacy of silencing in Hepa1-6 cell lines, a construct containing the targeting sequence 5 0 -GATCCGCACGGATC AACGAGAGTCTTTCAAGAGAAGACTCTCG TTGATCCGTGCTTTTTTG-3 0 was chosen for further animal experiments. Adenoviruses were propagated in 293T cell lines and purified using CsCl gradient centrifugation. Viral titration was performed using the Adeno-X Rapid Titer Kit (Clontech Laboratories, Inc., Mountain View, CA).
HEPATIC LIPID EXTRACTION AND LIVER STAINING
Lipid was extracted from liver using chloroform, methanol, and a phosphate-buffered saline mixture (2:1:0.75 ratio). Extracted lipid in the chloroform layer was dried overnight and dissolved in a solvent consisting of 95% isopropanol and 5% Triton X-100. TG concentration was determined by a commercial kit (Thermo Fisher Scientific, Rockford, IL) and normalized to wet liver weight. Hematoxylin and eosin and Oil Red O staining have been described. (15) 
WESTERN BLOT ANALYSIS
Western blotting was performed with protein extracts from liver as described. (21) Anti-HES6 antibody (Thermo Fisher Scientific) was used in a 1:500 dilution. After visualizing HES6 proteins, the membrane was stripped for b-actin antibody incubation (1:1,000 dilution; Novus Biologicals, Littleton, CO).
MOUSE HEPATOMA CELLS TRANSDUCED WITH ADENOVIRAL CONSTRUCTS
The Hepa1-6 mouse hepatoma cell line was transduced with AdHes6 or AdshHes6 to test the effect of HES6 on lipid accumulation in vitro. Cells were split into six-well plates and maintained in Dulbecco's modified Eagle's medium plus 10% bovine growth serum (GE Life Sciences, Logan, UT) until 90% confluency. Cells at 90% confluency were treated with adenoviral constructs (adenovirus without an insert [Adnull], AdHes6, or AdshHes6) at 1 3 10 10 plaqueforming units/mL in triplicates. Cells were further maintained for 3 days and replenished with fresh media containing 1 mM free fatty acids (palmitic acid and oleic acid, 1:2) plus 1% albumin. Cells were harvested 24 hours later for Hes6 expression or TG analysis. Intracellular TG was extracted using ethanol saponification. (22) Accumulated TG was quantified by comparing with values obtained from cells in media without free fatty acids and normalized to protein content.
RNA ISOLATION AND QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
Total RNA was isolated from livers and white adipose tissues of experimental mice or cultured Hepa 1-6 cells using Trizol reagents (ThermoFisher Scientific). RNA isolated from human liver tissues of normal patients and patients with NASH have been described. (23) cDNA was synthesized from the isolated RNA using PrimeScript RT Master Mix (Clontech). Quantitative PCR (qPCR) analysis was performed as described. (21) Gene-specific primer sequences were obtained from PrimerBank (http://pga.mgh.harvard. edu/primerbank) and reported publications (Supporting Table S2 ).
TRANSIENT TRANSFECTION AND CHROMATIN IMMUNOPRECIPITATION
Luciferase reporter genes driven by mouse Pparg2 promoters were constructed by insertion of PCRamplified promoters into pGL3 reporter plasmid (Promega, Madison, WI). All plasmids and transfection assays used in this study have been described. (15) HeLa and Hepa1-6 were maintained in Dulbecco's modified Eagle's medium plus 10% bovine growth serum. A chromatin immunoprecipitation (ChIP) assay was also performed to identify recruitment of HNF4a and HES6 to the Pparg2 promoter region using mouse liver as described. (15) 
ELECTROPHORETIC MOBILITY SHIFT ASSAY
To test direct binding of HNF4a to a specific site on the Pparg2 promoter, an electrophoretic mobility shift assay (EMSA) was performed using a radiolabeled DNA probe as described. (24) HNF4a protein was expressed using the TNT coupled reticulocyte lysate system (Promega, Madison, WI). Anti-HNF4a antibody (C-19) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Full sequences of the DNA probes used in this study are described in Supporting Table S3 .
STATISTICS
Values are presented as means 6 SEM. The Student t test was used to compare two different groups. P values less than 0.05 were considered significantly different between groups.
Results

OVEREXPRESSION OF Hes6 AMELIORATES HEPATIC LIPID ACCUMULATION INDUCED BY A WESTERN DIET
Our previous study suggested that a novel transcriptional cascade was responsible for hepatic lipid metabolism. (15) We showed that all-retinoic acid treatment or overexpression of a hepatic RAR induced Hes6 gene expression in mouse liver; this inhibits lipogenic programs and facilitates faster lipid mobilization, thereby protecting the liver from lipid accumulation induced by a WD. In the current study, we explored a direct role of HES6 in the transcriptional cascade and hepatic lipid metabolism. To test the effect of overexpression of Hes6 in mouse liver, C57BL/6 mice fed the WD for 2 months were injected with AdHes6 or Adnull through the tail vein and maintained for an additional 2 weeks under the WD regimen. The AdHes6-injected mice displayed less pale liver than the Adnullinjected control mice (Fig. 1A, left panel) . Liver histology indicated that Hes6 overexpression markedly attenuated hepatic steatosis developed by WD feeding (Fig.  1A , center panel). Their triglyceride level was significantly less than that of the control mice (Fig. 1A , right panel). A similar pattern was observed with hepatic cholesterol level, although statistical significance was not manifested (Supporting Fig. S1A ). However, levels of serum TG and cholesterol were not affected by Hes6 overexpression. AdHes6 injection clearly induced Hes6 messenger RNA (mRNA) and protein expressions by around 2-fold in the liver but minimally in white adipose tissue, demonstrating its liver-specific expression ( Fig. 1B; Supporting Fig. S2A ). Hes6 overexpression significantly inhibited the expression of its downstream target genes Pparg2 and Fsp27. (15) However, the mRNA levels of its upstream transcription factors Shp and Rara were not affected. We observed a comparable amount of food intake and body weight change between the two groups after virus injection (Supporting Fig. S3A ).
To determine whether the reduction of hepatic lipid accumulation observed in an animal model is a direct consequence of Hes6 overexpression, we overexpressed the Hes6 gene in Hepa1-6 cells, a mouse hepatoma cell line, using AdHes6 and measured intracellular TG concentration after free fatty acid challenge. AdHes6 transduction efficiently increased Hes6 expression and decreased intracellular TG levels, which is in accord with the results from the animal study (Fig. 1C) .
SILENCING Hes6 EXACERBATES FAT ACCUMULATION IN THE LIVER
To explore the effect of Hes6 silencing on hepatic fat accumulation and expression of genes in the transcriptional cascade, AdshHes6 was constructed and delivered into 3-month-old wild-type C57BL/6 mice.
Immediately after adenoviral injection, the mice were subjected to WD feeding for 2 weeks. The adenovirus injection effectively reduced the Hes6 mRNA and protein expressions by 65% and 53%, respectively, in the mouse liver, which resulted in increased mRNA expressions of Pparg2 and Fsp27 but not Pparg1, Shp, and Hnf4a ( Fig. 2B; Supporting Fig. S2B ). In contrast to the overexpression, silencing resulted in significant hepatic fat accumulation after the 14-day WD feeding regimen, as demonstrated by gross morphology and Oil Red O staining ( Fig. 2A, left panel) . Both triglyceride and cholesterol levels were significantly increased in the liver of AdshHes6-injected mice compared to those of their Adnull-injected counterparts ( Fig. 2A;  Supporting Fig. S1B ). However, serum TG and cholesterol levels, food intake, and body weight changes were comparable between the two groups as observed in AdHes6 injection (Supporting Figs. S1B, S2B). . Their Hes6 mRNA and intracellular TG levels were quantified and plotted with SEM. *P < 0.05; **P < 0.01; ***P < 0.005. Abbreviations: H&E, hematoxylin and eosin; pfu, plaque-forming units; WT, wild-type.
We also tested Hes6 silencing in Hepa1-6 cells using AdshHes6. The infection with AdshHes6 strongly blunted Hes6 mRNA expression and caused significantly higher TG accumulation in the cells when compared to Adnull infection (Fig. 2C) . Along with the result from Hes6 overexpression, this in vitro observation suggests that HES6 directly regulates TG accumulation in hepatocytes.
HNF4a AND HES6 DIRECTLY REGULATE EXPRESSION OF THE Pparg2 GENE
Martinez-Jimenez et al. (20) reported that HNF4a directly up-regulates the expression of Pparg and that Hes6 inhibits the expression through an active and direct repression on HNF4a transcriptional activity. However, they presented mRNA levels of Pparg1 while performing ChIP and transient transfection assays were performed with Pparg2 promoter, generating ambiguities in the regulation of Pparg gene transcription by HES6 and HNF4a. As the two Pparg genes are regulated by two separate promoters, (25, 26) we performed a transient transfection assay using mouse 2.5-kb Pparg2 promoter-driven luciferase reporter to test direct activation of Pparg2 by HNF4a. Cotransfection of Hnf4a expression plasmid significantly activated the reporter gene, and the addition of Hes6 inhibited HNF4a-mediated transactivation (Fig. 3A) . In contrast to our earlier study, (27) SHP failed to inhibit HNF4a transcriptional activity, suggesting a strong promoter specificity in the formation of the SHP/HNF4a or HES6/HNF4a complex. To confirm the direct effect of HNF4a on the 2.5-kb promoter activity, we constructed a Pparg2 promoter lacking the potential binding site (Fig. 4, section  D1 ). To our surprise, transient transfection assays revealed that the D1 deletion reporter still retained the responsiveness to HNF4a in HeLa and Hepa1-6 (negatively regulated because of high endogenous Hes6 expression) cell lines (Fig. 3B) , strongly suggesting that something other than the potential binding site reported (20) is responsible for the regulation mediated by HNF4a. However, ChIP assays clearly demonstrated that HNF4a and HES6 were recruited to a Pparg2 promoter region around -0.25 kb but not -3.0 kb upstream from the transcription start site (Fig. 3C ).
IDENTIFICATION OF THE HNF4a BINDING SITE RESPONSIBLE FOR Pparg2 GENE EXPRESSION
In order to locate the HNF4a binding site, additional deletion reporter constructs were generated (Fig. 4 , section D2-D4) and used in a transient transfection assay. The D3 deletion mutant failed to respond to Hnf4a cotransfection, indicating that a potential HNF4a binding site is in the D3 region (Fig.  5, left panel) . Based on the consensus HNF4a sequences identified by protein binding microarrays (28) (Fig.  5B, Consensus) , we located the potential HNF4a binding sequence in the D3 region (bold and underlined letters in Figs. 4 and 5B, line S3). Interestingly, the previously reported potential binding sequence (Fig. 5B, line S1 ) is different from the consensus. To confirm HNF4a specificity for the identified sequence, base mutations were introduced into the sequence as (Fig. 5A, right  panel) . EMSA was performed to further examine direct binding of HNF4a using 30-mer oligonucleotides containing the sequence as a probe (Fig. 5C ). HNF4a expressed in reticulocytes clearly formed a shifted radiolabeled band (lane 2), which was further shifted by anti-HNF4a antibody (lane 5). The band was significantly diminished by competition with a 10-fold excess of cold self-probe (lane 3) but not with cold probe with the mutations (lane 4). A probe containing an earlier reported sequence failed to compete the HNF4a binding activity away (lane 6). All these results clearly indicate that the newly identified sequence is truly a key element regulating Pparg2 gene expression by HNF4a and HES6, thereby controlling hepatic lipid accumulation. As the HNF4a response sequence is conserved between human PPARG2 and mouse Pparg2 promoter, (29) we quantified mRNA levels of genes in the proposed transcriptional cascade in the previously studied livers of patients with NASH who had significantly higher hepatic TGs than normal subjects. (23) Along with the reported higher TG values, these liver samples exhibited higher inflammatory and fibrotic gene expression, typical characteristics of FIG. 4 . Nucleotide sequence of the 1.5-kb mouse Pparg2 promoter region and its deletion mutants used for this study. The four deletion regions are highlighted with arrows above the regions. The putative binding site for HNF4a (20) is indicated as bold on the sequence. The newly identified HNF4a binding site is highlighted as underlined and bold in the D3 region. The transcription start site and translation start ATG site are marked with a right arrow and bold, respectively. NASH, than normal samples (Fig. 6A) . Although statistical significance was lacking due to a small sample size, the patients with NASH displayed a similar pattern of the gene expression observed from mouse studies: lower HES6 expression and higher PPARG2 and CIDEC gene expression than those from normal subjects, as shown in Fig. 6B , suggesting that the regulatory role of HES6 and PPARG2 in the development of nonalcoholic fatty liver disease (NAFLD) is conserved, at least in human and mouse.
PPARc2 ACTIVATES BOTH Fsp27a and Fsp27b TRANSCRIPTION IN DIET-INDUCED HEPATIC STEATOSIS
A recent study reported that the liver predominantly produces FSP27b, which contains 10 more amino acids at the N-terminal of the originally reported FSP27 (FSP27a). (30) According to the study, the transcription of Fsp27b starts at 950 base pairs downstream (27) S1, a putative HNF4a binding sequence as suggested by Martinez-Jimenez et al. (20) S3, a newly identified HNF4a binding sequence responsible for HES6 mediated down-regulation of Pparg2 expression. S3mut, bases are underlined for the point mutations used in EMSA. (C) EMSA was performed using HNF4a translated in vitro and a radiolabeled probe containing the newly identified HNF4a binding sequence (S3). A competition assay was performed with cold probes containing the self, point mutants (mut), and a putative HNF4a binding site suggested by Martinez-Jimenez et al. (20) (S1). Anti-HNF4a antibody was also used to confirm specificity of the band. of the original Fsp27a and is directly regulated by cyclic-adenosine monophosphate-response-element binding protein H (CREBH), whereas Fsp27a is regulated by PPARc. The suggested role of CREBH and FSP27b in hepatic fat accumulation by fasting has also been observed in ethanol-induced hepatic steatosis. (31) Thus, we tested the involvement of Creb3l3 and Fsp27b in diet-induced hepatic steatosis using quantitative PCR analysis. We found a 6-month WD regimen strongly up-regulated hepatic Pparg2, Fsp27a, and Fsp27b expressions and significantly reduced Hes6 mRNA level (Fig. 7A) . As noted in the report, Fsp27b expression was several hundred-fold higher than the Fsp27a expression, confirming Fsp27b as the major hepatic isoform (data not shown). However, the WD failed to induce Cleb3l3 (a gene encoding CREBH) expression in the liver. These results strongly suggest that PPARc2, not CREBH, is the major activator for both Fsp27a and Fsp27b expressions in the development of diet-induced hepatic steatosis. In addition, Hes6 overexpression in the liver repressed the mRNA levels of Fsp27a and Fsp27b, while knockdown by shHes6 markedly induced these levels (Fig. 7B) . In contrast, the expression of Creb3l3 was affected marginally by these modifications of Hes6 expression. Moreover, the level of CREB3L3 mRNA was reduced in the livers of patients with NASH, arguing against its potential role in development of NAFLD (Fig. 7C ). In our model system where hepatic steatosis was manipulated by WD or Hes6 expression, PPARc2 appears to be the main activator for Fsp27b expression and hepatic fat accumulation, whereas CREBH affects the pathway minimally, if any, in response to those challenges. CREBH may be an important regulator for the hepatocyte-specific expression of Fsp27b and TG mobilization during a fed-fast cycle. Induction of PPARc2 may synergistically increase Fsp27b promoter activity in conjunction with CREBH DNA binding during WD feeding.
Discussion
The liver functions as a major organ to uptake fatty acids from circulation and deliver them along with newly synthesized ones to peripheral tissues. In certain pathophysiologic conditions, the liver fails to maintain homeostasis, which results in lipid accumulation and leads to development of hepatic steatosis. The progression of NAFLD was initially proposed as a two-hit theory in which hepatic steatosis is a prerequisite condition for development of more serious NAFLD, such as NASH, fibrosis, and cirrhosis. (32) A simple basis for the development of steatosis is an imbalance between the output and input of hepatic lipids. The output is represented by fatty acid oxidation and VLDL secretion and the input by de novo lipogenesis and uptake of fatty acids from circulation. Our previous studies suggested that orphan nuclear receptor Shp knockout mice are protected from diet-induced hepatic steatosis due to increased fatty acid oxidation by relieving its repression on PPARa target genes. In a subsequent study, we additionally suggested that Shp is involved in regulating a novel transcriptional cascade, which determines the fate of hepatic lipid through controlling lipogenesis and adipogenesis. PPARc2, a master regulator for adipogenesis and lipogenesis in adipocytes, was suggested to be a major downstream transcription factor in the proposed cascade. The expression of the Pparg2 gene in the liver is repressed in normal conditions, possibly to accommodate quick fat mobilization. Expression levels in patients with NASH were compared to those in normal subjects and plotted with SEM. *P < 0.05; **P < 0.01. Abbreviations: ACTA2, smooth muscle actin alpha 2; COL1A2, collagen type I alpha 2 chain; IL, interleukin; TNF, tumor necrosis factor.
In agreement with this, hepatic expression of Pparg2 not Pparg1 is increased in obesity induced by diet or genetic manipulations, and its increase is believed to be an initial step in the development of hepatic steatosis. (8, 33, 34) Martinez-Jimenez et al. (20) proposed that HES6 and HNF4a directly suppress Pparg transcription, and our previous study demonstrated that expression of Hes6 and Pparg2 are reciprocally related to each other in mouse models of diet-induced obesity. (15) Although a regulatory function of HES6 in hepatic Pparg transcription has been suggested, its direct involvement in development of steatosis was challenged by the transgenic mouse study in which hepatic overexpression of Hes6 did not result in any significant changes in lipid accumulation on either the fed or fasted conditions of chow-fed mice. (20) However, a recent report studying animals with liver-specific knockout of Fos-related antigen 1 (Fra1), a FIG. 7. Expression of hepatic Fsp27b and its upstream regulators Pparg2 and Creb3l3 in mice and in patients with NASH. Indicated hepatic mRNA levels from (A) 6-month WD-fed WT mice or (B) Hes6-overexpressed (AdHes6) or Hes6-silenced (AdshHes6) mice were quantified and compared to levels from corresponding controls using real-time qPCR. (C) Indicated hepatic gene expressions were also evaluated in normal individuals and patients with NASH. The relative gene expression was plotted with SEM. *P < 0.05; **P < 0.01; ***P < 0.005 compared to control or normal samples. component of activator protein 1 dimers, emphasized the importance of the transcriptional cascade PPARc2 and downstream targets in the development of NAFLD by cellular stress. (35) The current study was aimed to understand the regulation of Pparg2 expression by HES6 and HNF4a and critically test the function of HES6 on hepatic lipid accumulation on a WD challenge. Overexpression of Hes6 attenuated hepatic fat accumulation and Pparg2 gene transcription in WD-fed C57BL/6 mice. In contrast, silencing of Hes6 with shRNA exacerbated hepatic fat accumulation and further increased Pparg2 transcription. Activation of Pparg2 promoter by HNF4a and inhibition of the activity by addition of HES6 in transient transfection assays clearly indicated that the two transcription factors directly regulate Pparg2 expression. ChIP and EMSA identified an HNF4a binding site, which is almost identical to the consensus sequence reported by Bolotin et al. (28) and is also conserved in human PPARG2 promoter. (29) Although a strong interaction between HNF4a and HES6 had been manifested (20) and a molecular mechanism of HES6-mediated transcriptional repression has been proposed in myogenesis, (36) how Pparg2 gene is repressed by these two transcription factors remains elusive. In an EMSA assay, HNF4a binding was diminished with HES6 addition, which argues against the proposed repression mechanism and the recruitment of Hes6 on the Pparg2 promoter (data not shown; Fig. 3C ). Nonetheless, the data from human subjects with NASH suggest that the proposed transcriptional cascade is also similarly important in hepatic lipid homeostasis in human. Although the liver biopsies from subjects with NASH displayed a significant increase in the expression of inflammatory genes, a direct link between Hes6 expression and NASH development requires further investigation.
Unlike Shp -/-mice, the expression of many of the major genes involved in hepatic fatty acid oxidation and synthesis were not affected by overexpression or silencing of Hes6 despite changes in fat accumulation with WD feeding (data not shown). Among the tested genes, stearoyl CoA desaturase 1 was significantly upor down-regulated by overexpression or silencing of Hes6, respectively (Supporting Fig. S2 ). As desaturation of fatty acids was demonstrated as a critical step in the hepatic fat accumulation with high-carbohydrate diet feeding, (37) we concluded that stearoyl CoA desaturase 1 also plays a role in the hepatic lipid metabolism affected by the Hes6-Pparg2 cascade along with FSP27b. Even though other important fatty acid synthesis or oxidation genes were not affected by the cascade, clear changes in hepatic fat accumulation in mouse models of HES6 highlight the importance of the role of FSP27 in lipid droplet protection and the development of hepatic steatosis. (10, 11) As evidenced by a recent observation, the rates of fatty acid esterification into hepatic TGs are dependent on the levels of plasma fatty acids. (38) Our study emphasizes that hepatic fatty acid uptake and subsequent TG use represented by TG hydrolysis or VLDL production are crucial factors determining the development of hepatic steatosis. Therefore, induction of Fsp27 and stearoyl CoA desaturase 1 by the Hes6-Hnf4a-Pparg2 axis must be sufficient to result in significant fat accumulation in the liver without an increase in de novo fatty acid synthesis in our animal models.
A recent study identified the liver-specific Fsp27 transcript (Fsp27b), a longer version of original Fsp27 (Fsp27a), which encodes an additional 10 amino acids at its N-terminal end under the control of a basic leucine zipper transcription factor, CREBH. (30, 39) The study argued strongly against an earlier report that has shown regulation of hepatic Fsp27 expression by PPARc. (9) However, an expression profile of mRNAs in the regulatory axis revealed that hepatic CREBH was not induced in the settings of WD feeding, Hes6 gene silencing, and NASH, where fat accumulation and induction of Paprg2 and Fsp27 expressions were evident. Thus, PPARc2 not CREBH plays a more critical role in Fsp27 expression and subsequent fat accumulation in these contexts. Although further study is required, CREBH appears to be an important cofactor for maintaining expression of Fsp27b in a liverspecific manner, and induction of Pparg2 activates transcription of both isoforms of Fsp27 effectively as shown in our results. Therefore, HES6, a novel transcriptional repressor of Pparg2 expression, should be considered an important regulator for hepatic fat metabolism in response to a variety of physical and environmental conditions.
